NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Nutriband's AVERSA™ FENTANYL Patch and Executive Order on Fentanyl
TL;DR
Nutriband's AVERSA FENTANYL abuse-deterrent patch could capture $80-200M in annual U.S. sales, offering a competitive edge in the opioid market.
Nutriband combines its AVERSA abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch to deter abuse while maintaining medical access for chronic pain patients.
This technology reduces fentanyl patch abuse and accidental pediatric exposure, improving safety while ensuring access for severe chronic pain patients.
Nutriband is developing the first abuse-deterrent opioid patch, addressing a critical gap in pain management with innovative transdermal technology.
Found this article helpful?
Share it with your network and spread the knowledge!
The press release addresses the Trump Administration's Executive Order designating illicit fentanyl as a weapon of mass destruction and clarifies that this does not apply to FDA-approved prescription fentanyl therapies, while highlighting Nutriband's development of AVERSA™ FENTANYL, an abuse-deterrent fentanyl patch.
AVERSA™ FENTANYL could be the first abuse-deterrent opioid patch, addressing concerns about transdermal fentanyl patch abuse and accidental pediatric exposure while maintaining access for patients who need prescription fentanyl products for severe chronic pain.
AVERSA™ FENTANYL combines Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch to deter abuse and reduce accidental exposure. The AVERSA™ technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Inc. is partnering with Kindeva to develop AVERSA™ FENTANYL, combining Nutriband's AVERSA™ technology with Kindeva's FDA-approved fentanyl patch.
Nutriband estimates AVERSA™ FENTANYL could reach peak annual U.S. sales of $80 million to $200 million, with an initial focus on the U.S. market and a goal of broader availability in major global medical markets.
The release clarifies that the Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction should not be conflated with FDA-approved prescription fentanyl therapies, which are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients.
The company's website is www.nutriband.com, and the latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with its lead product under development being an abuse-deterrent fentanyl patch incorporating its AVERSA™ technology.
Curated from InvestorBrandNetwork (IBN)
